Clinical trial status | Vaccine name | Description | Type of vaccine | Mono/Pauci/Poly antigenic | Proposed use | Clinical end-points | Efficacy tested in NHP and/or Bovine models | Efficacy greater than BCG in NHP/Bovine models |
---|---|---|---|---|---|---|---|---|
Phase III | DAR-901 | Whole cell non-tuberculous mycobacteria | Inactivated mycobacteria | Polyantigen | Boost BCG | Prevention of tuberculosis disease in adolescents and adults | Bovine | No16 |
Phase IIb | MVA85A/AERAS-485 | Modified Vaccinia Ankara vector expressing antigen 85A | Viral vector | Monoantigen | Boost BCG | Prevention of infection, disease and reactivation | NHP and Bovine | No5 6 |
Phase IIb | AERAS-402/Crucell Ad35 | Adenoviral vector expressing antigen 85A, 85B, TB10.4 | Viral vector | Pauciantigen | Boost BCG | Prevention of infection and disease | No | – |
Phase II | VPM 1002 | Recombinant BCG strain expressing listeriolysin and carrying a urease deletion mutation | Recombinant live attenuated mycobacteria | Polyantigen | Boost/Replace BCG | Prevention of infection and disease | No | – |
Phase II | RUTI | Liposomed fragments of Mtb | Whole cell vaccine | Polyantigen | Adjunct to LTB INH prophylaxis/Boost BCG | Prevention of infection, disease and reactivation | No | – |
Phase II | M72 | Recombinant fusion protein of Mtb antigens RV1196 and Rv0125 with AS01 adjuvant | Recombinant protein | Pauciantigen | Replace BCG | Prevention of infection and disease | NHP | Yes17 |
Phase II | H1-IC31 | Recombinant fusion protein of Mtb antigens 85B, ESAT-6 with IC31 adjuvant | Recombinant protein | Pauciantigen | Boost/Replace BCG | Prevention of infection and disease | No | – |
Phase I | AdAg85A | Recombinant adenoviral vector expressing antigen 85A | Viral vector | Monoantigen | Boost/Replace BCG | Prevention of infection and disease | Bovine | No5 |
Phase I | AERAS-422 | Recombinant BCG strain expressing mutation PfoA and Mtb antigens 85A, 85B and TB10.4 | Recombinant live attenuated mycobacteria | Polyantigen | Replace BCG | Prevention of infection and disease | No | – |
Phase I | rBCG30 | Recombinant BCG strain expressing Mtb antigen 85B | Recombinant live attenuated mycobacteria | Polyantigen | Boost BCG | Prevention of infection and disease | No | – |
Phase I | ID93/GLA-SE | Recombinant fusion protein of Mtb antigens Rv2608, Rv3619, Rv3620 and Rv1813 with GLA-SE adjuvant | Recombinant protein | Pauciantigen | Boost/Replace BCG | Prevention of infection and disease | No | – |
Phase I | H4-IC31 | Recombinant fusion protein of Mtb antigens 85B, TB10.4 with IC31 adjuvant | Recombinant protein | Pauciantigen | Boost BCG | Prevention of infection and disease | No | – |
Phase I | H1-CAF01 | Recombinant fusion protein of Mtb antigens 85B, ESAT-6 with CAF01 adjuvant | Recombinant protein | Pauciantigen | Boost/Replace BCG | Prevention of infection and disease | No | – |
Phase I | H56-IC31 | Recombinant fusion protein of Mtb antigens 85B, ESAT-6 and Rv2660 with IC31 adjuvant | Recombinant protein | Pauciantigen | Boost/Replace BCG | Prevention of infection, disease and reactivation | NHP | No18 |
Mtb, Mycobacterium tuberculosis; NHP, non-human primate; BCG, Bacillus Calmette-Guerin.